SE

SeQuent Scientific LtdNSE SEQUENT Stock Report

Last reporting period 31 Mar, 2024

Updated 08 Nov, 2024

Last price

Market cap $B

0.207

Micro

Exchange

XNSE - National Stock Exchange Of India

SEQUENT.NS Stock Analysis

SE

Uncovered

SeQuent Scientific Ltd is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-1/100

Low score

Market cap $B

0.207

Dividend yield

0.22 %

Shares outstanding

249.48 B

SeQuent Scientific Ltd. manufactures and produces veterinary pharmaceuticals and specialty chemicals. The company is headquartered in Mumbai, Maharashtra and currently employs 478 full-time employees. The company went IPO on 2016-03-10. The firm provides a wide range of animal health products, including finished dose formulations, active pharmaceutical ingredients (APIs), as well as analytical services. The firm operates through the pharmaceuticals segment. The firm is focused on various therapies, such as targeted are anthelmintics (endo and ecto parasiticides), anti-protozoals, nutraceuticals, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-infectives and dermatology. The company is specialized in analytical and bio analytical services to support the API, pharmaceutical, personal care and nutraceutical companies. The company provides analytical solutions, including method validation, stability, microbiology for APIs and finished products in a variety of dosage forms as per pharmacopoeia monographs, customer developed methods or in-house method development. Its subsidiaries include Alivira Animal Health Limited and SeQuent Research Limited.

View Section: Eyestock Rating